Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -196.03% is 113% below its 2-year average of -91.84%, near the low end of its 2-year range (-196.03%–-34.05%).
As of the fiscal period ended Tuesday, June 30, 2026. 50.99% below its 12-month average of -129.83%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -196.03%.
RETURN ON EQUITY (ROE)
-196.03%
RETURN ON EQUITY (ROE) AVG TTM
-129.83%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-50.99%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-366.63%
vs the sector median at left
Zenas BioPharma, Inc.
Market Cap
$1.70B
Return on Equity (ROE)
-196.03%
TTM Avg
-129.83%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.71B
Return on Equity (ROE)
-40.41%
TTM Avg
-45.75%
3Y Avg
-30.11%
5Y Avg
-18.95%
Market Cap
$1.71B
Return on Equity (ROE)
-45.58%
TTM Avg
-35.59%
3Y Avg
-51.70%
5Y Avg
-41.50%
Market Cap
$1.73B
Return on Equity (ROE)
-54.96%
TTM Avg
-60.50%
3Y Avg
-51.30%
5Y Avg
-42.73%
Market Cap
$1.73B
Return on Equity (ROE)
N/A
TTM Avg
94.61%
3Y Avg
224.41%
5Y Avg
83.14%
Market Cap
$1.73B
Return on Equity (ROE)
15.35%
TTM Avg
-64.31%
3Y Avg
-71.44%
5Y Avg
-70.74%
Market Cap
$1.74B
Return on Equity (ROE)
-43.94%
TTM Avg
-43.41%
3Y Avg
-41.23%
5Y Avg
-29.16%
Market Cap
$1.75B
Return on Equity (ROE)
-5.30%
TTM Avg
-6.97%
3Y Avg
-4.32%
5Y Avg
-7.48%
Market Cap
$1.73B
Return on Equity (ROE)
-49.19%
TTM Avg
-59.18%
3Y Avg
-54.84%
5Y Avg
-44.72%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zenas BioPharma, Inc. (ZBIO) | $1.70B | -196.03% | -129.83% | N/A | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.71B | -40.41% | -45.75% | -30.11% | -18.95% |
| Personalis, Inc. (PSNL)vs › | $1.71B | -45.58% | -35.59% | -51.70% | -41.50% |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.73B | -54.96% | -60.50% | -51.30% | -42.73% |
| Xeris Biopharma Holdings, Inc. (XERS)vs › | $1.73B | N/A | 94.61% | 224.41% | 83.14% |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.73B | 15.35% | -64.31% | -71.44% | -70.74% |
| Novocure Ltd (NVCR)vs › | $1.74B | -43.94% | -43.41% | -41.23% | -29.16% |
| Surgery Partners, Inc. (SGRY)vs › | $1.75B | -5.30% | -6.97% | -4.32% | -7.48% |
| Absci Corporation (ABSI)vs › | $1.73B | -49.19% | -59.18% | -54.84% | -44.72% |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.63B | 17.72% | 5.08% | 0.03% | -3.88% |
ROE
-196.0%
ROA
-69.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -196.03% |
| 2026-03-31 | -126.60% |
| 2025-12-31 | -156.00% |
| 2025-09-30 | -96.68% |
| 2025-06-30 | -73.87% |
| 2025-03-31 | -57.25% |
| 2024-12-31 | -50.24% |
| 2024-09-30 | -35.88% |
| 2024-06-30 | -34.05% |
